Endor Health Lists Sandoz, Apotex, Teva, Taro, Aspen in Queue

A patient-facing explainer published by Endor Health identifies Sandoz Canada, Apotex, Teva Canada, Taro Pharmaceuticals, Aspen and Pharmacare Canada among the companies whose generic semaglutide submissions are before Health Canada, with nine submissions under review as of January 2026 [Source: endorhealth.com/article/generic-ozempic-coming-to-canada].

The applicant roster

Endor Health's overview lists Sandoz Canada, Apotex, Teva Canada, Taro Pharmaceuticals, Aspen and Pharmacare Canada among the companies with semaglutide submissions under Health Canada review, and states the regulator's target review timeline is 180 days, though complex submissions can take longer [Source: endorhealth.com/article/generic-ozempic-coming-to-canada]. The explainer notes that semaglutide is a synthetic peptide delivered via injection pen, and that Health Canada requires manufacturers to demonstrate that generic versions match the brand-name drug in safety, efficacy and quality [Source: endorhealth.com/article/generic-ozempic-coming-to-canada].

First approvals already on the books

Health Canada authorized the first generic semaglutide injection on April 28, 2026, a submission filed by Dr. Reddy's Laboratories, and the department said at the time it was reviewing eight other submissions for generic semaglutide by different companies [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html]. The BMJ subsequently reported that a second generic, from Apotex, was also approved, leaving seven applications still under review [Source: bmj.com/content/393/bmj-2026-597166].

Why the queue matters for pricing

Endor Health cited Vancouver endocrinologist Dr. Ehud Ur, who told The Canadian Press that "the biggest barrier to taking Ozempic is not side effects or worries about its efficacy but its cost," adding that monthly costs of two to four hundred dollars are "just impossible" for many patients [Source: endorhealth.com/article/generic-ozempic-coming-to-canada]. The article placed current brand-name semaglutide prices at approximately $200 to $400 per month in Canada, with Ozempic typically in the lower end of that range and Wegovy in the higher end [Source: endorhealth.com/article/generic-ozempic-coming-to-canada].

Current pharmacy prices listed on GLP1Prices.ca span $215 to $663 for Ozempic and $270 to $550 for Wegovy, broadly consistent with the Endor Health range at the lower-dose end but extending higher for certain pen strengths. Readers can verify dose-specific listings against the generic semaglutide tracker.

Insurer preparation

Frédéric Leblanc, a pharmacist at iA Financial, was quoted as saying insurers are "preparing for everything we need to do so that everybody benefits from a lower price, both in diabetes and eventually in weight management" [Source: endorhealth.com/article/generic-ozempic-coming-to-canada]. The explainer notes that many insurance plans typically prefer or require the lower-cost generic version once available, and that patients who prefer to stay on a branded version may need to pay the cost difference, depending on plan terms [Source: endorhealth.com/article/generic-ozempic-coming-to-canada]. Plan members can check current rules via the insurance coverage checker.

Tirzepatide remains separate

The Endor Health article emphasizes that only semaglutide is losing patent protection, and that Eli Lilly's tirzepatide products Mounjaro and Zepbound remain under patent in Canada with no imminent patent expiry [Source: endorhealth.com/article/generic-ozempic-coming-to-canada]. Tirzepatide targets both GLP-1 and GIP receptors rather than GLP-1 alone, the article notes [Source: endorhealth.com/article/generic-ozempic-coming-to-canada].

What patients are told to expect

• Health Canada is reviewing nine submissions as of January 2026, with named applicants including Sandoz Canada, Apotex, Teva Canada, Taro Pharmaceuticals, Aspen and Pharmacare Canada [Source: endorhealth.com/article/generic-ozempic-coming-to-canada].
• The regulator's target review timeline is 180 days, with complex submissions potentially taking longer [Source: endorhealth.com/article/generic-ozempic-coming-to-canada].
• Provincial public coverage criteria vary, and Wegovy for weight management remains largely uncovered by public plans despite recommendations from Canada's Drug Agency [Source: endorhealth.com/article/generic-ozempic-coming-to-canada].

Additional background and patient questions are addressed on the GLP1Prices.ca FAQ.

This article is for informational purposes only and does not constitute medical advice.